BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Korzenik JR. IBD: A Vascular Disorder? The Case for Heparin Therapy: . Inflammatory Bowel Diseases 1997;3:87-94. [DOI: 10.1097/00054725-199706000-00004] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
Number Citing Articles
1 Defilippis EM, Barfield E, Leifer D, Steinlauf A, Bosworth BP, Scherl EJ, Sockolow R. Cerebral venous thrombosis in inflammatory bowel disease: Cerebral venous thrombosis in IBD. Journal of Digestive Diseases 2015;16:104-8. [DOI: 10.1111/1751-2980.12212] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
2 Bloom S, Kiilerich S, Lassen MR, Forbes A, Leiper K, Langholz E, Irvine EJ, O’Morain C, Lowson D, Orm S. Low molecular weight heparin (tinzaparin) vs. placebo in the treatment of mild to moderately active ulcerative colitis. Aliment Pharmacol Ther. 2004;19:871-878. [PMID: 15080848 DOI: 10.1111/j.1365-2036.2004.01926.x] [Cited by in Crossref: 41] [Cited by in F6Publishing: 42] [Article Influence: 2.4] [Reference Citation Analysis]
3 Farrell RJ, Banerjee S, Peppercorn MA. Recent advances in inflammatory bowel disease. Crit Rev Clin Lab Sci 2001;38:33-108. [PMID: 11256517 DOI: 10.1080/20014091084173] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.5] [Reference Citation Analysis]
4 Song DY, Lawrie W, Abrams RA, Kafonek DR, Bayless TM, Welsh JS, Deweese TL. Acute and late radiotherapy toxicity in patients with inflammatory bowel disease. International Journal of Radiation Oncology*Biology*Physics 2001;51:455-9. [DOI: 10.1016/s0360-3016(01)01629-7] [Cited by in Crossref: 52] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
5 Zezos P, Papaioannou G, Nikolaidis N, Patsiaoura K, Papageorgiou A, Vassiliadis T, Giouleme O, Evgenidis N. Low-molecular-weight heparin (enoxaparin) as adjuvant therapy in the treatment of active ulcerative colitis: a randomized, controlled, comparative study. Aliment Pharmacol Ther 2006;23:1443-53. [PMID: 16669959 DOI: 10.1111/j.1365-2036.2006.02870.x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 2.3] [Reference Citation Analysis]
6 Shen J, Ran ZH, Tong JL, Xiao SD. Meta-analysis: The utility and safety of heparin in the treatment of active ulcerative colitis. Aliment Pharmacol Ther. 2007;26:653-663. [PMID: 17697199 DOI: 10.1111/j.1365-2036.2007.03418.x] [Cited by in Crossref: 61] [Cited by in F6Publishing: 62] [Article Influence: 4.4] [Reference Citation Analysis]
7 Vrij AA, Jansen JM, Schoon EJ, de Bruïne A, Hemker HC, Stockbrügger RW. Low molecular weight heparin treatment in steroid refractory ulcerative colitis: clinical outcome and influence on mucosal capillary thrombi. Scand J Gastroenterol Suppl. 2001;234:41-47. [PMID: 11768560 DOI: 10.1080/003655201753265091] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 1.8] [Reference Citation Analysis]
8 Papa A, Danese S, Gasbarrini A, Gasbarrini G. Review article: potential therapeutic applications and mechanisms of action of heparin in inflammatory bowel disease. Aliment Pharmacol Ther. 2000;14:1403-1409. [PMID: 11069310 DOI: 10.1046/j.1365-2036.2000.00860.x] [Cited by in Crossref: 52] [Cited by in F6Publishing: 55] [Article Influence: 2.5] [Reference Citation Analysis]
9 Jmour O, Pellat A, Colson-Durand L, To NH, Latorzeff I, Sargos P, Sobhani I, Belkacemi Y. [Radiation therapy in patients with inflammatory bowel disease. A review]. Bull Cancer 2018;105:517-22. [PMID: 29653817 DOI: 10.1016/j.bulcan.2018.02.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]